Who Supplies Amoxicillin to India from IRAQ

Importing finished pharmaceutical formulations containing Amoxicillin into India requires compliance with the Directorate General of Foreign Trade (DGFT) regulations, including obtaining an Importer Exporter Code (IEC). The Central Drugs Standard Control Organisation (CDSCO) mandates that all imported drugs be registered with a valid Form 40 or 41, depending on the product type. For Amoxicillin formulations under HS Code 30041030, a No Objection Certificate (NOC) from the CDSCO is necessary. The registration process involves submitting detailed product information, manufacturing licenses, and stability data. The timeline for import drug registration can vary but typically ranges from 6 to 12 months, depending on the completeness of the application and regulatory reviews.

Imported Amoxicillin formulations must undergo quality testing at CDSCO-approved laboratories to ensure compliance with Indian Pharmacopoeia standards. Batch-wise testing is required, with each batch accompanied by a Certificate of Analysis (CoA) confirming compliance. Stability data, particularly for ICH Zone IV conditions, must be provided to demonstrate the product's shelf-life under Indian climatic conditions. Upon arrival, customs drug inspectors perform port inspections to verify the authenticity and quality of the shipments. If a batch fails to meet the required standards, it may be rejected, leading to potential delays or the need for re-exportation.

In January 2026, the Indian government amended its import policy to set a Minimum Import Price (MIP) for penicillins, including Amoxicillin and its related salts. This measure aims to curb the dumping of cheap imports, particularly from China, by establishing a floor price for these antibiotics. The MIP applies to all imports of Amoxicillin formulations, ensuring that imported products are priced competitively and fairly within the Indian market. This policy change is part of India's broader strategy to protect domestic pharmaceutical manufacturers and maintain the quality of imported medicines.

India imports finished Amoxicillin formulations to meet the domestic demand for various dosage forms, including tablets, capsules, syrups, and injections. While India has a robust pharmaceutical manufacturing sector, certain patented or specialized formulations not produced domestically necessitate imports. The market size for Amoxicillin formulations in India is substantial, with imports contributing to approximately 15% of the total market share. The reliance on imports is driven by the need for specific dosage forms, quality standards, and competitive pricing that domestic manufacturers may not always offer.

The import duty structure for Amoxicillin formulations under HS Code 30041030 includes a Basic Customs Duty (BCD) of 10%, a Social Welfare Surcharge (SWS) of 10% on the BCD, and an Integrated Goods and Services Tax (IGST) of 12%. There are no exemptions or preferential rates for imports from Iraq. The total landed duty percentage is approximately 23.6%, comprising the BCD, SWS, and IGST. This duty structure is designed to protect domestic manufacturers while ensuring that imported products are competitively priced.

India sources Amoxicillin formulations from Iraq due to competitive pricing and the availability of specific dosage forms not produced domestically. Iraq's pharmaceutical industry offers formulations that meet international quality standards, making them attractive to Indian importers. While other suppliers like China, Germany, and the United States also export Amoxicillin formulations to India, Iraq's share in the Indian market is approximately 2%, indicating a niche but growing presence. The competitive advantage lies in Iraq's ability to provide cost-effective products without compromising on quality, catering to the price-sensitive segments of the Indian market.

India imports Amoxicillin formulations from Iraq due to the availability of specific dosage forms and formulations not produced domestically. Iraq's pharmaceutical industry offers cost-effective products that meet international quality standards, making them attractive to Indian importers. The importation of these formulations helps India meet the diverse therapeutic needs of its population, especially in regions where domestic production is limited.

When compared to other origins like China, the European Union, and the United States, Iraq offers competitive pricing and specific formulations that may not be available from these suppliers. While China and the EU provide a wide range of pharmaceutical products, Iraq's niche offerings and cost advantages make it a valuable source for certain Amoxicillin formulations. The U.S. offers high-quality products but at higher prices, which may not be suitable for all segments of the Indian market.

Importing from Iraq presents certain risks, including potential political instability, currency fluctuations, and logistical challenges. However, these risks are mitigated by establishing strong relationships with reliable suppliers, maintaining adequate inventory levels, and staying informed about the geopolitical situation. There have been no significant shortages reported in recent years, indicating a stable supply chain.